# Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
Canonical URL: https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance
Ticker: XERS
Company: Xeris Pharmaceuticals
Source: Xeris Pharmaceuticals
Published: 2026-03-02 12:00 EST
Original Source URL: https://xerispharma.com
## Summary

Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Mar.

## Article Body
Achieved record quarterly and full-year total revenue of $86 million and $292 million, respectively Provides full year 2026 total revenue guidance range of $375 million to $390 million Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO --(BUSINESS WIRE)--Mar.
## Recent Company News
- 2026-05-07 11:00 EST — [Xeris Biopharma Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-first-quarter-2026-financial-results) — Source: Xeris Pharmaceuticals
- 2026-04-23 11:30 EST — [Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026) — Source: Xeris Pharmaceuticals
- 2026-04-03 20:15 EST — [Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Xeris Pharmaceuticals
- 2026-03-02 12:00 EST — [Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance) — Source: Xeris Pharmaceuticals
- 2026-02-26 22:55 EST — [Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit](https://biopharmsignal.com/news/XERS/xeris-biopharma-subsidiaries-file-recorlevr-patent-infringement-lawsuit) — Source: Xeris Pharmaceuticals
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)